Diabetes Mellitus, Type 2 Clinical Trial
— MET-INF-T2DOfficial title:
Metabolic Inflexibility of the Heart as a Predictor of Occurrence of Heart Failure in Patients With Type 2 Diabetes
In the type 2 diabetic population, some patients are particularly at risk of developing early heart failure. Finding markers to identify these at-risk individuals is therefore an important scientific objective in order to avoid/delay the development of heart failure. The protocol will be proposed to type 2 diabetic patients hospitalized for insulin therapy upon admission to the diabetology department and healthy volunteers.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | October 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Patients - Patient aged over 18 and under 75 - Type 2 diabetes treated with bitherapy for at least 6 months - Unbalanced diabetes (HbA1c = 10%) - Indication for insulin therapy (introduction of a slow-acting insulin injection per day or adding rapid-acting insulins before meals in the event of a slow-acting or semi-acting insulin injection already present on admission) - BMI < 40 kg/m2 - Cardiovascular examination without clinically significant abnormality - LVEF > 50% (measured by echocardiography) - Free from any acute intercurrent pathology for more than 10 days, - Accept the constraints of the protocol and sign the informed and free consent - Be affiliated to a French social security scheme or entitled Healthy volunteers - Be over 18 and under 75 - Have a BMI < 30 kg/m² - Be asymptomatic - Normal clinical examination - Normal resting 12-lead ECG - Normal biological balance (fasting blood glucose, HBA1c, ionogram, creatinine, NFS, BNP / pro-BNP, troponin) - Accept the constraints of the protocol and sign the informed and free consent - Be affiliated to a French social security scheme or entitled Exclusion Criteria: Patients - Current or recent infections (< 10 days) - Neoplastic disorders (except carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular (except controlled arterial hypertension), psychiatric, neurological, chronic respiratory failure - Presence of renal insufficiency defined as an estimated glomerular filtration rate < 30mL/min/1.73m2 according to the MDRD formula - Rhythm and/or conduction disorder not previously known and discovered during the 12-lead ECG performed at inclusion - Known cardiovascular pathology (arteriopathy and/or cardiomyopathy) - Contraindications to MRI with injection of gadolinium: claustrophobia, pacemaker, metallic foreign body, anxiety attack, nausea, vomiting, panic attack, vertigo, malaise without traumatic consequences, allergy to contrast products, renal failure defined by an estimated glomerular filtration rate < 30mL/min/1.73m2 according to the MDRD formula, diffusion of the contrast product during its infusion - Contraindication for regadenoson injection: hypersensitivity to the active substance or to any of the excipients, second or third degree atrioventricular (AV) block or sinoatrial node dysfunction, unless these patients are carriers an operational pacemaker, unstable angina not stabilized by medical treatment, severe hypotension, decompensated heart failure - Pregnant or breastfeeding women - Persons deprived of their liberty by judicial decision or benefiting from legal protection (under guardianship or curatorship) - Abuse of alcohol or narcotics - Patient under AME (state medical aid) - Participation in another interventional research involving the human person or being in the exclusion period at the end of a previous research involving the human person Healthy volunteers - Contraindications to MRI: claustrophobia, metallic foreign body, anxiety attack, nausea, vomiting, panic attack, vertigo, malaise without traumatic consequences - Have kidney disease with GFR < 30 mL/min - Known cardiac pathology - Personal cardiovascular history - Primary cardiomyopathy or familial congenital heart disease - Being deprived of liberty or under legal protection (under guardianship or curatorship) - Witness under AME (state medical aid) - Participation in another interventional research involving the human person or being in the exclusion period at the end of a previous research involving the human person - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Pitié-Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Left ventricular myocardial longitudinal strain measured by MRI (%) | Myocardial longitudinal strain measured by dynamic MRI images (%) throughtout feature tracking strategy | 15 days | |
Secondary | Left ventricular myocardial radial strain measured by dynamic MRI images (%) throughtout feature tracking strategy | 15 days | ||
Secondary | Extracellualar volume (%) and collagene fraction (%) measured from MRI images | 15 days | ||
Secondary | Rest ratio in myocardial perfusion reserve calculated from rest and stress MRI images | 15 days | ||
Secondary | Measurement of early and late filling wave velocities (E, A) and myocardial longitudinal velocity (E') | 15 days | ||
Secondary | Myocardial triglycerides fraction measured from proton MR spectroscopy | 15 days | ||
Secondary | Epicardial fat volume measured from ECG gated Dixon MRI images | 15 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |